Modality
ADC
MOA
KRASG12Di
Target
PI3Kα
Pathway
Fibrosis
Cervical Ca
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
→ Jul 2030
Phase 1Current
NCT05217748
1,802 pts·Cervical Ca
2017-11→2030-07·Completed
1,802 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-094.3y awayPh2 Data· Cervical Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Complet…
Catalysts
Ph2 Data
2030-07-09 · 4.3y away
Cervical Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05217748 | Phase 1/2 | Cervical Ca | Completed | 1802 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |